The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Synergy and Order Effects of Antibiotics and Phages in Killing Pseudomonas aeruginosa Biofilms
Open accessAbstract
In contrast to planktonic cells, bacteria imbedded biofilms are notoriously refractory to treatment by antibiotics or bacteriophage (phage) used alone. Given that the mechanisms of killing differ profoundly between drugs and phages, an obvious question is whether killing is improved by combining antibiotic and phage therapy. However, this question has only recently begun to be explored. Here, in vitro biofilm populations of Pseudomonas aeruginosa PA14 were treated singly and with combinations of two phages and bactericidal antibiotics of five classes. By themselves, phages and drugs commonly had only modest effects in killing the bacteria. However some phage-drug combinations reduced bacterial densities to well below that of the best single treatment; in some cases, bacterial densities were reduced even below the level expected if both agents killed independently of each other (synergy). Furthermore, there was a profound order effect in some cases: treatment with phages before drugs achieved maximum killing. Combined treatment was particularly effective in killing in Pseudomonas biofilms grown on layers of cultured epithelial cells. Phages were also capable of limiting the extent to which minority populations of bacteria resistant to the treating antibiotic ascend. The potential of combined antibiotic and phage treatment of biofilm infections is discussed as a realistic way to evaluate and establish the use of bacteriophage for the treatment of humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Molecular characterization of Legionella pneumophila-induced interleukin-8 expression in T cells
Takamatsu, R., Teruya, H., Takeshima, E., Ishikawa, C., Matsumoto, K., Mukaida, N., Li, J.-D., Heuner, K., Higa, F., Fujita, J., et al. (2010) · BMC Microbiology · doi:10.1186/1471-2180-10-1 · Cited by 337
RetractedMethods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Bacterial Biofilms: A Common Cause of Persistent Infections
Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999) · Science · doi:10.1126/science.284.5418.1318 · Cited by 12,167
Bacterial biofilms: from the Natural environment to infectious diseases
Hall-Stoodley, L., Costerton, J. W., & Stoodley, P. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro821 · Cited by 7,143
Understanding biofilm resistance to antibacterial agents
Davies, D. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1008 · Cited by 2,781
Ecology of prokaryotic viruses
Weinbauer, M. G. (2004) · FEMS Microbiology Reviews · doi:10.1016/j.femsre.2003.08.001 · Cited by 1,771
Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?
Livermore, D. M. (2002) · Clinical Infectious Diseases · doi:10.1086/338782 · Cited by 1,453
Here a virus, there a virus, everywhere the same virus?
Breitbart, M., & Rohwer, F. (2005) · Trends in Microbiology · doi:10.1016/j.tim.2005.04.003 · Cited by 854
The changing epidemiology of resistance
Hawkey, P. M., & Jones, A. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp256 · Cited by 773
Cited by
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S., & Pardesi, K. R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00539 · Cited by 1,644
Phage Therapy in the Postantibiotic Era
Gordillo Altamirano, F. L., & Barr, J. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00066-18 · Cited by 1,180
Gu Liu, C., Green, S. I., Min, L., Clark, J. R., Salazar, K. C., Terwilliger, A. L., Kaplan, H. B., Trautner, B. W., Ramig, R. F., & Maresso, A. W. (2020) · mBio · doi:10.1128/mbio.01462-20 · Cited by 409
Considerations for the Use of Phage Therapy in Clinical Practice
Suh, G. A., Lodise, T. P., Tamma, P. D., Knisely, J. M., Alexander, J., Aslam, S., Barton, K. D., Bizzell, E., Totten, K. M. C., Campbell, J. L., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02071-21 · Cited by 378
Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy
Tagliaferri, T. L., Jansen, M., & Horz, H.-P. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00022 · Cited by 345
Current challenges and future opportunities of phage therapy
Pires, D. P., Costa, A. R., Pinto, G., Meneses, L., & Azeredo, J. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa017 · Cited by 340
Shariati, A., Arshadi, M., Khosrojerdi, M. A., Abedinzadeh, M., Ganjalishahi, M., Maleki, A., Heidary, M., & Khoshnood, S. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1025633 · Cited by 337
Mechanisms and clinical importance of bacteriophage resistance
Egido, J. E., Costa, A. R., Aparicio-Maldonado, C., Haas, P.-J., & Brouns, S. J. J. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab048 · Cited by 325
Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures
Brives, C., & Pourraz, J. (2020) · Palgrave Communications · doi:10.1057/s41599-020-0478-4 · Cited by 322
Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review
Chegini, Z., Khoshbayan, A., Taati Moghadam, M., Farahani, I., Jazireian, P., & Shariati, A. (2020) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-020-00389-5 · Cited by 321
Pires, D., Melo, L., Vilas Boas, D., Sillankorva, S., & Azeredo, J. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.09.004 · Cited by 312
Proximate and ultimate causes of the bactericidal action of antibiotics
Baquero, F., & Levin, B. R. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00443-1 · Cited by 307
Self-citationMaciejewska, B., Olszak, T., & Drulis-Kawa, Z. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-8811-1 · Cited by 222
Phages and their potential to modulate the microbiome and immunity
Federici, S., Nobs, S. P., & Elinav, E. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00532-4 · Cited by 222
Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways
Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18081115 · Cited by 56
Metadata
- Authors
- Chaudhry, W. N., Concepción-Acevedo, J., Park, T., Andleeb, S., Bull, J. J., & Levin, B. R.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-01-11
- Volume
- 12
- Issue
- 1
- Pages
- e0168615
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2572554549
- Cited by
- 394
- References
- 41
- FWCI
- 24.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.